High-Throughput Screening Identifies Proteasome Inhibitors as Potentiators of Type III Interferon JAK-STAT Signaling and Antiviral Immunity
This study identifies proteasome inhibitors as selective potentiators of Type III interferon antiviral immunity by increasing cell-surface IL-10Rβ levels, thereby enhancing JAK-STAT signaling and bridging the efficacy gap between Type III and Type I interferons.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of a preprint that has not been peer-reviewed. It is not medical advice. Do not make health decisions based on this content. Read full disclaimer
The human body is constantly under siege by invisible invaders, from the common cold to more dangerous respiratory viruses. To defend itself, our immune system deploys a sophisticated arsenal of chemical messengers called interferons. Think of these as the body's emergency alarms and command centers. When a cell detects a virus, it releases interferons that warn neighboring cells to lock down and fight back. There are different types of these signals, but two are particularly important for our first line of defense: Type I and Type III. Type I interferons are powerful and act everywhere in the body, but their strength comes with a cost; they can trigger severe inflammation and make patients feel very sick. Type III interferons, on the other hand, are more specialized. They work primarily at the body's barriers, like the lining of the lungs and the gut, where most viruses enter. They are safer and cause less inflammation, but they are also weaker, often failing to stop a virus before it takes hold. Scientists have long wanted to find a way to make these safer, barrier-focused signals stronger without triggering the dangerous side effects of the more aggressive type.
A team of researchers set out to solve this problem by looking for small chemical compounds that could boost the power of Type III interferons. They started by building a new kind of test, a high-speed screening system designed to watch how cells react to these signals in real time. Instead of waiting days to see if a virus was stopped, they looked at what happened within minutes. When a cell receives an interferon signal, it activates a specific set of proteins inside, which act like a switch turning on the cell's defenses. The researchers created a method to measure how brightly these switches lit up. They tested nearly 9,000 different chemical compounds on human lung cells to see if any of them could make the Type III signal shine brighter.
The search yielded a surprising discovery. The compounds that worked best were not new drugs invented for this purpose, but a known class of chemicals called proteasome inhibitors. These are substances that block a specific recycling machine inside the cell, a machine that normally breaks down old or damaged proteins. The researchers found that when they added these inhibitors, the cells became much more sensitive to Type III interferons. The chemical switches inside the cells lit up much brighter and stayed on longer. Crucially, this boost happened specifically for the Type III signal; the Type I signal, which was already very strong, did not get significantly stronger. This selectivity is vital because it means the treatment could enhance the safe, barrier-focused defense without overloading the system with the toxic effects of the aggressive Type I response.
To understand why this happened, the scientists looked closely at the surface of the cells, where the interferon signals are received. They discovered that the Type III interferon receptor has a weak point: it often lacks enough of one specific part, a subunit called IL-10Rβ, to work at full capacity. It is as if the cell has a radio with a missing antenna, so the signal comes in weak and fuzzy. The proteasome inhibitors stopped the cell from breaking down this missing part. As a result, more of these receptors stayed on the cell surface, creating a larger pool of antennas ready to catch the signal. With more receptors available, the Type III interferon could send a much stronger message, turning the cell's defenses up to a level that was previously only possible with the more toxic Type I interferon.
The researchers then tested if this stronger signal actually helped the cells fight a real virus. They exposed the cells to a virus that glows green when it replicates. Without any help, the Type III interferon stopped some of the virus, but many cells still glowed brightly. When the researchers added the proteasome inhibitor along with the Type III interferon, the virus was almost completely stopped, and the cells remained dark. The cells were protected as well as they would have been by the powerful Type I interferon, but without the need for that stronger, riskier signal. This confirmed that the chemical boost was not just a laboratory curiosity; it translated directly into a real biological defense.
The study also ruled out several other possibilities. The researchers checked if the chemicals were simply making the cells produce more receptor genes, but they found that the amount of genetic instructions for these receptors did not change. The boost came entirely from keeping the existing proteins on the surface longer, not from building new ones. They also confirmed that this effect was not unique to one type of cell, as they saw the same results in different cell lines. While the paper focuses on the mechanics of this discovery, it suggests a clear path forward: these existing chemicals, or new versions of them, could potentially be used to create treatments that help the body fight off respiratory and gut viruses more effectively, using the body's own safer defense system but with much greater power. The work establishes that the availability of specific receptor parts on the cell surface is a critical control point that can be manipulated to improve how we fight infection.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.